Lakefront Biotherapeutics (LKFT) Share-based Compensation (2016 - 2022)

Lakefront Biotherapeutics (LKFT) has reported Share-based Compensation for 7 consecutive years, with $16.4 million the latest figure, recorded in Q1 2022.

• Quarterly Share-based Compensation fell 22.01% year-over-year to $16.4 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $101.7 million (up 30.92% YoY) and the FY2023 annual result came in at $64.5 million, down 35.92% from the prior year.
• Share-based Compensation slipped to $16.4 million in Q1 2022 per LKFT's latest filing, from $29.7 million in the prior quarter.
• Over the last five years, Share-based Compensation for LKFT reached as high as $34.6 million in Q2 2020 and fell as low as $5.7 million in Q1 2018.
• A 5-year average of $14.7 million and a median of $11.6 million in 2019 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2018 — Share-based Compensation slumped 99.91% — and 2020, when it jumped 182.89%.
• Year by year, Share-based Compensation stood at $10.0 million in 2018, then grew by 16.14% to $11.6 million in 2019, then soared by 199.09% to $34.6 million in 2020, then declined by 14.15% to $29.7 million in 2021, then sank by 44.86% to $16.4 million in 2022.
• According to Business Quant data, Share-based Compensation over the past three periods registered $16.4 million, $29.7 million, and $21.0 million for Q1 2022, Q2 2021, and Q1 2021 respectively.